RecruitingNCT06750575

Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease

The Effect of Furosemide on Protein-Bound Uremic Toxin Plasma Levels and Excretion in Patients with Chronic Kidney Disease


Sponsor

UMC Utrecht

Enrollment

34 participants

Start Date

Jun 10, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to examine the interaction between the diuretic furosemide and certain toxins called protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). The main question it aims to answer is: what is the effect of furosemide on plasma levels of PBUTs in patients with CKD? Besides, the investigators will also look at the effect of furosemide on the excretion of PBUTs via the urine. Participants will be included in the study once they will be prescribed furosemide as part of routine patient care. Before they start with the furosemide treatment, patients will undergo the following: * Blood pressure measurement * Blood sample withdrawal * Urine sample collection * 12-hour urine collection Then, one to four weeks after starting with furosemide treatment, patients will undergo the following: * Blood pressure measurement * Blood sample prior to furosemide intake (Tmin) * Blood sample withdrawal 90 minutes after furosemide intake (Tmax: time at which the highest furosemide plasma level is expected) * Urine sample collection 60-120 minutes after furosemide intake * 12-hour urine collection The investigators expect furosemide to increase plasma levels of PBUTs by decreasing the renal excretion of the toxins.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether starting treatment with a water pill (diuretic) called furosemide in people with chronic kidney disease (CKD) can help remove a type of harmful waste product called protein-bound uremic toxins (PBUTs) from the blood. These toxins build up when the kidneys are not working properly and may contribute to further kidney and heart damage. **You may be eligible if...** - You are 18 or older - You have been diagnosed with chronic kidney disease (Stage 3–5), meaning your kidney function has been reduced for at least 3 months - Your doctor has decided to start you on furosemide as part of your regular care **You may NOT be eligible if...** - You are already taking furosemide - You have liver disease causing jaundice (high bilirubin) - You are on dialysis (peritoneal or hemodialysis) or have end-stage kidney failure with no remaining urine output - You are starting other new medications at the same time that could affect the toxin levels being measured Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTInvasive measurements

Blood and urine samples will be collected during the study.


Locations(1)

University Medical Center Utrecht (UMCU)

Utrecht, Utrecht, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06750575


Related Trials